Scholars Central

Conference abstractPublished 2 Feb 2022

What Multiple Sclerosis took and Stem Cells gave back

Authors: Kav Partap Karamthasingh

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Kav Partap Karamthasingh is a 37 year old from Trinidad and Tobago. She has suffered with Multiple Sclerosis since the age of 17. She suffered paralysis, bladder issues, blurred vision, weakness and fatigue. These symptoms plague her life and her condition deteriorated slowly. At the age of 27 she lost her vision and began desperately looking for a treatment. She discovered Stem Cell treatments. This treatment was extremely controversial at the time and expensive but she put all her faith in and hoped for the best. She was the first patient in her country to be treated with Stem Cells for Multiple Sclerosis. She underwent the treatment in May but her condition did not improve until August. After August she regained her bodily functions and has been testing her limits since that day 10 years ago. She continued on her part time career of teaching but evolved into an entrepreneur so that she can support her healthy lifestyle. Kav is the author of Conquering 20, an autobiography that tells her inspirational story of her survival.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Stem Cell Research & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Stem Cell Research & Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Kav Partap Karamthasingh”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels